New Era of Preventing End-Stage Kidney Disease Act
U.S. Congress · HR1518 ·
What the bill says
Introduced 2025-02-24. Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Summary (plain-language)
New Era of Preventing End-Stage Kidney Disease Act This bill establishes regional centers of excellence, postgraduate fellowships, and training for health professionals relating to the diagnosis and treatment of rare kidney disease. It also requires the Department of Health and Human Services (HHS) to conduct various studies on rare kidney disease. Specifically, it authorizes the National Institute of Diabetes and Digestive and Kidney Diseases to award funding to public and private nonprofit entities for establishing regional centers of excellence that will increase public awareness, conduct research, and develop resources for diagnosing and treating rare kidney diseases. A center may receive such funding for up to five years, unless extended by the institute. The bill also requires health professions schools receiving a grant from the Health Resources and Services Administration (HRSA) Centers of Excellence program to award fellowships for training on preventing, diagnosing, and treating rare kidney disease in disproportionately impacted populations. Also, the bill expands the priorities of HRSA’s Primary Care Training and Enhancement program to include training for health care workers to care for individuals with kidney disease. Additionally, HHS must conduct several studies and report to Congress on topics such as treating rare kidney disease in disproportionately affected populations, eliminating the need for dialysis or kidney transplants, and increasing public awareness of rare kidney disease.
Sponsors
- Gus M. Bilirakis (primary)
- Sanford D. Bishop, Jr.
- Julia Brownley
- Jack Bergman
- Troy Balderson
- Janelle S. Bynum
- Henry Cuellar
- Kathy Castor
- Yvette D. Clarke
- Judy Chu
- J. Luis Correa
- Dan Crenshaw
- Jason Crow
- Mike Carey
- Danny K. Davis
- Donald G. Davis
- Neal P. Dunn
- Veronica Escobar
- Brian K. Fitzpatrick
- Mike Flood
- Al Green
- Andrew R. Garbarino
- Abraham J. Hamadeh
- Glenn Ivey
- Henry C. "Hank" Johnson, Jr.
- Jonathan L. Jackson
- Young Kim
- Jennifer A. Kiggans
- Zoe Lofgren
- Ted Lieu
- Susie Lee
- Mike Levin
- Michael Lawler
- James P. McGovern
- Carol D. Miller
- Robert Menendez
- Sarah McBride
- Jerrold Nadler
- Eleanor Holmes Norton
- Jay Obernolte
- Alexandria Ocasio-Cortez
- Mark Pocan
- Scott H. Peters
- Deborah K. Ross
- Patrick Ryan
- Terri A. Sewell
- Bradley Scott Schneider
- Darren Soto
- Thomas R. Suozzi
- Haley M. Stevens
- Bennie G. Thompson
- Mike Thompson
- Paul Tonko
- Rashida Tlaib
- Jefferson Van Drew
- Gabe Vasquez
- Eugene Simon Vindman
- Joe Wilson
- James R. Walkinshaw
Text versions
- Introduced in House — 2025-02-24 — XML
What analysts say
No nonpartisan analysis on file for this measure yet.
What politicians say
No linked claims or utterances yet — no one on record has cited this measure to justify a public argument.
Action History
| Date | Action |
|---|---|
| 2025-02-24 | Introduced in House |
| 2025-02-24 | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
Lobbying on this bill
Showing 17 of 17 bill mentions.
Honesty note: each filer below disclosed lobbying on this bill — that much the filing tells us. But the dollar figure is their total lobbying spend for the whole quarter across all their issues, not the amount spent on this bill, and the filing never says whether they supported or opposed it.
Source: Senate LDA filings.